Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine for mild to moderate COVID-19
NCT04711863Phase 2Suspended
- Sponsor
- Asan Medical Center
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluvoxamine in coronavirus disease 2019 (COVID-19), sponsored by Asan Medical Center. Started Jan 2021; status: suspended.
02
Drugs
fluvoxamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04711863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711863.